[
  {
    "ts": null,
    "headline": "Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch",
    "summary": "Market Domination Overtime host Josh Lipton previews several of the biggest stories to come next week, including earnings results from Magnificent Seven companies Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Alphabet (GOOG, GOOGL), and Meta Platforms (META); Federal Reserve officials convening for their October FOMC meeting; and President Trump is meeting Chinese President Xi Jinping in South Korea as the government shutdown nears its fifth week. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=22c6dea8ce7264df11ed68c9230b2856ba3cd84794842af25c6654197546a9dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761346800,
      "headline": "Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch",
      "id": 137215915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Market Domination Overtime host Josh Lipton previews several of the biggest stories to come next week, including earnings results from Magnificent Seven companies Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Alphabet (GOOG, GOOGL), and Meta Platforms (META); Federal Reserve officials convening for their October FOMC meeting; and President Trump is meeting Chinese President Xi Jinping in South Korea as the government shutdown nears its fifth week. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=22c6dea8ce7264df11ed68c9230b2856ba3cd84794842af25c6654197546a9dd"
    }
  },
  {
    "ts": null,
    "headline": "Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda",
    "summary": "Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock prospects ahead of the new data.",
    "url": "https://finnhub.io/api/news?id=94f6db346ac6041cafc9b21d9be4eb789d748bc3f96b578c050eadc169240b26",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761323040,
      "headline": "Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda",
      "id": 137203447,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1089342562/image_1089342562.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock prospects ahead of the new data.",
      "url": "https://finnhub.io/api/news?id=94f6db346ac6041cafc9b21d9be4eb789d748bc3f96b578c050eadc169240b26"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Non-Oncology Drugs Q3 Performance: What to Expect",
    "summary": "MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.",
    "url": "https://finnhub.io/api/news?id=a495ba94edf3b314d66e89597bef0a858857553e06dd26275f1c5513e830a084",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761314700,
      "headline": "Merck's Non-Oncology Drugs Q3 Performance: What to Expect",
      "id": 137216031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.",
      "url": "https://finnhub.io/api/news?id=a495ba94edf3b314d66e89597bef0a858857553e06dd26275f1c5513e830a084"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings",
    "summary": "LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.",
    "url": "https://finnhub.io/api/news?id=6628e9017c13810d4e5dd87125653beb0cd4b2cd310bbc6c24dc78e8d13c7010",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761312540,
      "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings",
      "id": 137215925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.",
      "url": "https://finnhub.io/api/news?id=6628e9017c13810d4e5dd87125653beb0cd4b2cd310bbc6c24dc78e8d13c7010"
    }
  },
  {
    "ts": null,
    "headline": "What To Expect From Gilead In Q3 2025",
    "summary": "Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting. Check out why GILD stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=b5f5ee55f87366db308381563df757bde2335123cbe5c6ab532f82054c10ff85",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761303403,
      "headline": "What To Expect From Gilead In Q3 2025",
      "id": 137202475,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/728909377/image_728909377.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting. Check out why GILD stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=b5f5ee55f87366db308381563df757bde2335123cbe5c6ab532f82054c10ff85"
    }
  },
  {
    "ts": null,
    "headline": "United States Lipid Nanoparticle Market Forecast and Competitive Analysis Report 2025-2033 Featuring Merck, Evonik, Genevant Sciences, CordenPharma, Arcturus, Ascendia, Acuitas, Croda",
    "summary": "The United States lipid nanoparticle market is projected to expand from $210.34 billion in 2024 to $519.18 billion by 2033, with a CAGR of 10.56%. This growth is driven by the increasing use of lipid nanoparticles (LNP) in drug delivery, RNA-based therapies, and vaccines. Key factors include advancements in nanotechnology, increased pharmaceutical and biotech investments, and growing adoption of RNA therapeutics. Despite challenges like high production costs and regulatory complexities, strategi",
    "url": "https://finnhub.io/api/news?id=4cc7d1f2c07db17078709e5ebdf9e530309f10801dfc3e4f5fe920a843ecd887",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761303060,
      "headline": "United States Lipid Nanoparticle Market Forecast and Competitive Analysis Report 2025-2033 Featuring Merck, Evonik, Genevant Sciences, CordenPharma, Arcturus, Ascendia, Acuitas, Croda",
      "id": 137216293,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The United States lipid nanoparticle market is projected to expand from $210.34 billion in 2024 to $519.18 billion by 2033, with a CAGR of 10.56%. This growth is driven by the increasing use of lipid nanoparticles (LNP) in drug delivery, RNA-based therapies, and vaccines. Key factors include advancements in nanotechnology, increased pharmaceutical and biotech investments, and growing adoption of RNA therapeutics. Despite challenges like high production costs and regulatory complexities, strategi",
      "url": "https://finnhub.io/api/news?id=4cc7d1f2c07db17078709e5ebdf9e530309f10801dfc3e4f5fe920a843ecd887"
    }
  }
]